Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Ermenegildo Zegna NV
ZGN
DexCom
DXCM
Workday
WDAY
US Stock MarketDetailed Quotes
TRVI Trevi Therapeutics
- 3.910
- -0.080-2.01%
Close Jan 24 16:00 ET
- 3.910
- 0.0000.00%
Post 16:02 ET
349.42MMarket Cap-8.89P/E (TTM)
4.050High3.815Low400.30KVolume4.050Open3.990Pre Close1.55MTurnover0.67%Turnover RatioLossP/E (Static)89.37MShares4.68052wk High5.92P/B235.53MFloat Cap1.35052wk Low--Dividend TTM60.24MShs Float10.620Historical High--Div YieldTTM5.89%Amplitude0.460Historical Low3.883Avg Price1Lot Size
Trevi Therapeutics News
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | DEFA14A: Others
Trevi Therapeutics | DEF 14A: Definitive information statements
Trevi Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Trevi Therapeutics | S-3/A: Registration statement for specified transactions by certain issuers (Amendment)
Trevi Therapeutics | S-3: Registration statement for specified transactions by certain issuers
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Trevi Therapeutics | DEFA14A: Others
Trevi Therapeutics | DEF 14A: Definitive proxy statements
Trevi Therapeutics | PRE 14A: Preliminary proxy statement not related to a contested matter or merger/acquisition
Trevi Therapeutics | 8-K: Current report
Trevi Therapeutics | 8-K: Current report